C4 Therapeutics IncNASDAQ:CCCC
- LAST PRICE5.3400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots5.1000/ 1
- Ask / Lots5.6700/ 4
- Open / Previous Close--- / 5.3400
- Day Range---
- 52 Week Range
- Volume52
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CCCC |
|---|---|---|
| 09:32 ET | 6494 | 5.36 |
| 09:34 ET | 1847 | 5.3 |
| 09:36 ET | 1862 | 5.39 |
| 09:38 ET | 700 | 5.3655 |
| 09:39 ET | 1400 | 5.37 |
| 09:41 ET | 300 | 5.32 |
| 09:43 ET | 11161 | 5.33 |
| 09:45 ET | 3600 | 5.305 |
| 09:48 ET | 1400 | 5.33 |
| 09:50 ET | 200 | 5.31 |
| 09:52 ET | 1471 | 5.2902 |
| 09:56 ET | 2900 | 5.32 |
| 09:57 ET | 1300 | 5.3 |
| 09:59 ET | 500 | 5.28 |
| 10:01 ET | 2690 | 5.29 |
| 10:03 ET | 664 | 5.32 |
| 10:06 ET | 400 | 5.31 |
| 10:08 ET | 1507 | 5.32 |
| 10:10 ET | 800 | 5.33 |
| 10:12 ET | 600 | 5.31 |
| 10:14 ET | 2300 | 5.3 |
| 10:15 ET | 5025 | 5.28 |
| 10:17 ET | 525 | 5.27 |
| 10:19 ET | 996 | 5.27 |
| 10:21 ET | 400 | 5.26 |
| 10:24 ET | 3952 | 5.2309 |
| 10:26 ET | 1447 | 5.2203 |
| 10:28 ET | 600 | 5.22 |
| 10:30 ET | 3694 | 5.22 |
| 10:32 ET | 650 | 5.21 |
| 10:33 ET | 1072 | 5.2116 |
| 10:35 ET | 1329 | 5.23 |
| 10:37 ET | 539 | 5.23 |
| 10:39 ET | 498 | 5.22 |
| 10:42 ET | 1400 | 5.2282 |
| 10:44 ET | 8114 | 5.21 |
| 10:46 ET | 500 | 5.21 |
| 10:48 ET | 400 | 5.22 |
| 10:50 ET | 325 | 5.2398 |
| 10:51 ET | 474 | 5.2 |
| 10:53 ET | 200 | 5.2 |
| 10:55 ET | 1200 | 5.21 |
| 10:57 ET | 300 | 5.21 |
| 11:00 ET | 1394 | 5.2 |
| 11:02 ET | 200 | 5.198 |
| 11:04 ET | 400 | 5.19 |
| 11:06 ET | 900 | 5.18 |
| 11:08 ET | 200 | 5.18 |
| 11:09 ET | 2733 | 5.2 |
| 11:11 ET | 900 | 5.205 |
| 11:13 ET | 1768 | 5.205 |
| 11:15 ET | 22799 | 5.225 |
| 11:18 ET | 700 | 5.225 |
| 11:20 ET | 800 | 5.225 |
| 11:22 ET | 2731 | 5.22 |
| 11:24 ET | 500 | 5.22 |
| 11:26 ET | 1600 | 5.23 |
| 11:29 ET | 3452 | 5.21 |
| 11:31 ET | 1619 | 5.2 |
| 11:33 ET | 1190 | 5.2 |
| 11:36 ET | 2498 | 5.2 |
| 11:38 ET | 1386 | 5.235 |
| 11:40 ET | 2328 | 5.235 |
| 11:42 ET | 1800 | 5.235 |
| 11:44 ET | 200 | 5.235 |
| 11:45 ET | 505 | 5.24 |
| 11:47 ET | 999 | 5.2475 |
| 11:49 ET | 307 | 5.24 |
| 11:51 ET | 905 | 5.25 |
| 11:54 ET | 300 | 5.25 |
| 11:56 ET | 1100 | 5.25 |
| 11:58 ET | 300 | 5.25 |
| 12:00 ET | 300 | 5.25 |
| 12:02 ET | 2224 | 5.23 |
| 12:03 ET | 1100 | 5.225 |
| 12:05 ET | 700 | 5.23 |
| 12:07 ET | 375 | 5.24 |
| 12:09 ET | 200 | 5.23 |
| 12:12 ET | 1500 | 5.23 |
| 12:14 ET | 325 | 5.23 |
| 12:16 ET | 5350 | 5.28 |
| 12:18 ET | 1300 | 5.28 |
| 12:20 ET | 1071 | 5.28 |
| 12:21 ET | 400 | 5.28 |
| 12:23 ET | 32893 | 5.32 |
| 12:25 ET | 25382 | 5.3 |
| 12:27 ET | 6781 | 5.32 |
| 12:30 ET | 3900 | 5.3 |
| 12:32 ET | 300 | 5.3 |
| 12:34 ET | 4192 | 5.29 |
| 12:36 ET | 4541 | 5.29 |
| 12:38 ET | 500 | 5.29 |
| 12:39 ET | 703 | 5.29 |
| 12:41 ET | 1706 | 5.29 |
| 12:43 ET | 929 | 5.29 |
| 12:45 ET | 4716 | 5.33 |
| 12:48 ET | 1584 | 5.32 |
| 12:50 ET | 3233 | 5.3 |
| 12:52 ET | 2058 | 5.3 |
| 12:54 ET | 400 | 5.3 |
| 12:56 ET | 1371 | 5.285 |
| 12:57 ET | 6886 | 5.3 |
| 12:59 ET | 1400 | 5.265 |
| 01:01 ET | 754 | 5.26 |
| 01:03 ET | 400 | 5.26 |
| 01:06 ET | 838 | 5.26 |
| 01:08 ET | 500 | 5.255 |
| 01:10 ET | 510 | 5.26 |
| 01:12 ET | 2580 | 5.26 |
| 01:14 ET | 1295 | 5.27 |
| 01:15 ET | 700 | 5.26 |
| 01:17 ET | 11226 | 5.26 |
| 01:19 ET | 1629 | 5.265 |
| 01:21 ET | 400 | 5.265 |
| 01:24 ET | 600 | 5.265 |
| 01:26 ET | 1915 | 5.265 |
| 01:28 ET | 2208 | 5.275 |
| 01:30 ET | 2100 | 5.2711 |
| 01:32 ET | 1920 | 5.28 |
| 01:33 ET | 2115 | 5.275 |
| 01:35 ET | 5827 | 5.28 |
| 01:37 ET | 5419 | 5.29 |
| 01:39 ET | 2219 | 5.285 |
| 01:42 ET | 36603 | 5.28 |
| 01:44 ET | 7389 | 5.28 |
| 01:46 ET | 834 | 5.285 |
| 01:48 ET | 607 | 5.285 |
| 01:50 ET | 1400 | 5.3 |
| 01:51 ET | 1000 | 5.305 |
| 01:53 ET | 4695 | 5.31 |
| 01:55 ET | 13040 | 5.27 |
| 01:57 ET | 8807 | 5.25 |
| 02:00 ET | 518 | 5.25 |
| 02:02 ET | 7575 | 5.19 |
| 02:04 ET | 2460 | 5.19 |
| 02:06 ET | 2214 | 5.1819 |
| 02:08 ET | 836 | 5.19 |
| 02:09 ET | 2784 | 5.22 |
| 02:11 ET | 700 | 5.22 |
| 02:13 ET | 1440 | 5.21 |
| 02:15 ET | 900 | 5.23 |
| 02:20 ET | 456 | 5.22 |
| 02:22 ET | 1832 | 5.24 |
| 02:24 ET | 2115 | 5.235 |
| 02:26 ET | 600 | 5.24 |
| 02:27 ET | 2700 | 5.26 |
| 02:29 ET | 700 | 5.25 |
| 02:31 ET | 400 | 5.24 |
| 02:33 ET | 600 | 5.235 |
| 02:36 ET | 100 | 5.235 |
| 02:38 ET | 857 | 5.235 |
| 02:40 ET | 3212 | 5.245 |
| 02:42 ET | 3312 | 5.26 |
| 02:44 ET | 2147 | 5.27 |
| 02:45 ET | 100 | 5.27 |
| 02:47 ET | 400 | 5.255 |
| 02:49 ET | 2985 | 5.265 |
| 02:51 ET | 1109 | 5.265 |
| 02:54 ET | 207 | 5.265 |
| 02:56 ET | 1131 | 5.265 |
| 02:58 ET | 3850 | 5.275 |
| 03:00 ET | 1600 | 5.255 |
| 03:02 ET | 1985 | 5.25 |
| 03:03 ET | 300 | 5.24 |
| 03:05 ET | 3014 | 5.25 |
| 03:07 ET | 5287 | 5.29 |
| 03:09 ET | 1233 | 5.28 |
| 03:12 ET | 1659 | 5.28 |
| 03:14 ET | 1212 | 5.27 |
| 03:16 ET | 900 | 5.285 |
| 03:18 ET | 2263 | 5.3 |
| 03:20 ET | 2000 | 5.295 |
| 03:21 ET | 12404 | 5.3 |
| 03:23 ET | 6578 | 5.295 |
| 03:25 ET | 1030 | 5.295 |
| 03:27 ET | 2379 | 5.29 |
| 03:30 ET | 3362 | 5.295 |
| 03:32 ET | 204497 | 5.33 |
| 03:34 ET | 2900 | 5.315 |
| 03:36 ET | 168412 | 5.32 |
| 03:38 ET | 4835 | 5.36 |
| 03:39 ET | 3175 | 5.3501 |
| 03:41 ET | 2395 | 5.35 |
| 03:43 ET | 1166 | 5.34 |
| 03:45 ET | 2737 | 5.34 |
| 03:48 ET | 2819 | 5.33 |
| 03:50 ET | 300 | 5.325 |
| 03:52 ET | 3202 | 5.31 |
| 03:54 ET | 4463 | 5.295 |
| 03:56 ET | 29849 | 5.35 |
| 03:57 ET | 29397 | 5.37 |
| 03:59 ET | 204245 | 5.34 |
Sep 30, 2024
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:01PM ET on Monday Sep 30, 2024 by Dow Jones
4:01PM ET on Monday Sep 30, 2024 by Dow Jones
Sep 13, 2024
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024, from 10:00AM ET on Friday Sep 13, 2024 by Dow Jones
10:00AM ET on Friday Sep 13, 2024 by Dow Jones
Sep 10, 2024
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen, from 7:00AM ET on Tuesday Sep 10, 2024 by Dow Jones
7:00AM ET on Tuesday Sep 10, 2024 by Dow Jones
Sep 8, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
C4 Therapeutics Inc | 370.3M | -2.8x | --- |
AC Immune SA | 335.4M | -4.5x | --- |
Iteos Therapeutics Inc | 353.7M | -3.2x | --- |
Taysha Gene Therapies Inc | 414.0M | -2.2x | --- |
Artiva Biotherapeutics Inc | 374.0M | 0.0x | --- |
Verve Therapeutics Inc | 399.4M | -1.8x | --- |
Company Information
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.
Contact Information
- Headquarters
- 490 Arsenal Way, Suite 120WATERTOWN, MA, United States 02472
- Phone
- 617-231-0700
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Ronald Cooper
- President, Chief Executive Officer, Director
- Andrew Hirsch
- Chief Financial Officer, Treasurer
- Kendra Adams
- Chief People Officer
- Kelly Schick
- Chief Scientific Officer
- Stewart Fisher
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $370.3M |
|---|---|
Revenue (TTM) | $29.4M |
Shares Outstanding | 69.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.05 |
EPS | $-1.90 |
Book Value | $4.07 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | 12.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -406.82% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
